Table 4.

Summary results of the Health Technology Appraisal meta-analyses of zanamivir and oseltamivir for the treatment of influenza¹

Drug and patients treated	Reduction (median days) in treatment groups compared with placebo (95%CI)
	Symptom alleviation		Time to return to normal activities
ITT population	Influenza positive	ITT population	Influenza positive
Zanamivir
Healthy individuals, aged 12–65 years	0·78 (0·26 to 1·31)	1·26 (0·59 to −1·93)	0·51 (−0·02 to 1·04)	0·46 (0·02 to 0·90)
At-risk individuals, including older than 65 years	0·93 (−0·05 to 1·90)	1·99 (0·90 to 3·08)	0·09 (−0·78 to 0·95)	0·2 (−0·79 to 1·19)
Healthy children	1·0 (0·50 to 1·50)	1·0 (0·40 to 1·60)	0·5 (−0·30 to 1·30)	0·5 (−0·40 to 1·40)
“All” individuals	0·94 (0·65 to 1·23)	1·26 (0·90 to 1·61)	0·37 (0·01 to 0·74)	0·37 (0·02 to 0·72)
Oseltamivir
Healthy individuals, aged 12–65 years	0·86 (0·31 to 1·42)	1·38 (0·79 to 1·96)	1·33 (0·70 to 1·96)	1·64 (0·69 to 2·58)
At-risk individuals, including older than 65 years	−0·34 (−0·71 to 1·40)	0·45 (−0·97 to 1·88)	2·45 (0·05 to 4·86)	3·0 (0·13 to 5·88)
Healthy children	0·87 (0·25 to 1·49)	1·49 (0·76 to 2·20)	1·25 (0·70 to 1·80)	1·86 (1·06 to 2·65)
“All” individuals	0·80 (0·41 to 1·18)	1·33 (0·90 to 1·77)	1·32 (0·91 to 1·73)	1·64 (1·17 to 2·10)

ITT=intention-to-treat.